

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France and Camberley, UK – 11 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 10 November 2020, Edwin Snape, a Non-Executive Director of the Company, purchased 1,080 ordinary shares of €1/15 each in the Company at a price of £7.15 per share. Following the purchase, Mr Snape is interested in 17,919 ordinary shares representing 0.025% of the issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Edwin Snape – Non-Executive Director				
2.	Reason for the Notification					
a)	Position/status	See 1(a) - classified as a PDMR of the Company				
b)	Initial notification/ Amendment	Initial Notification				
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	Novacyt S.A.				
b)	LEI	213800BWAC2BF295EG28				
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the Financial instrument, type of instrument	ordinary shares of €1/15 each				
	Identification code	FR0010397232				
b)	Nature of the transaction	Acquisition of Ordinary Shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>£7.15</td> <td>1,080</td> </tr> </tbody> </table>	Price	Volume	£7.15	1,080
Price	Volume					
£7.15	1,080					
d)	Aggregated information: · Aggregated volume · Price	N/A Single transaction as above <table border="1"> <thead> <tr> <th>Price</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>£7.17</td> <td>1,080</td> </tr> </tbody> </table>	Price	Volume	£7.17	1,080
Price	Volume					
£7.17	1,080					
e)	Date of the transaction	10 November 2020				
f)	Place of the transaction	AIM				

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black
+44 (0)20 7260 1000

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines
+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of *in vitro* and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com